30O.F ONCOTHERAPY SCIENCE INC.
- Market cap
- EUR 29.0M
- P/E
- -
- P/B
- 2.19x
- ROE
- -49.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is 30O.F undervalued?
Graham numberThe Graham number of ONCOTHERAPY SCIENCE INC. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ONCOTHERAPY SCIENCE INC. fundamental analysis
No fundamental analysis for ONCOTHERAPY SCIENCE INC. yet.
ONCOTHERAPY SCIENCE INC. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ONCOTHERAPY SCIENCE INC.
OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. The company's development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast canc…
Full company profileONCOTHERAPY SCIENCE INC. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ONCOTHERAPY SCIENCE INC. annual financial statements (JPY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 1.15B | 1.13B | 610M | 750M | 809M | 683M |
| Gross Profit | 114M | 41.7M | -178M | -12.8M | 14.0M | -1.78M |
| Operating Income | -2.05B | -1.11B | -1.12B | -798M | -810M | -1.14B |
| EBITDA | - | -1.12B | -1.29B | -812M | -907M | -1.15B |
| Net Income | -2.57B | -1.12B | -1.29B | -815M | -911M | -1.16B |
| EPS | -13 | -5.81 | -5.92 | -3.00 | -2.37 | -2.83 |
| Balance Sheet | ||||||
| Total Assets | 2.69B | 1.51B | 867M | 1.16B | 2.36B | 2.61B |
| Total Liabilities | 705M | 656M | 514M | 426M | 217M | 265M |
| Shareholders' Equity | 1.98B | 855M | 354M | 729M | 2.14B | 2.35B |
| Cash & Short-term Investments | 1.84B | 1.12B | 528M | 834M | 2.09B | 2.33B |
| Cash Flow | ||||||
| Operating Cash Flow | -2.07B | -795M | -1.23B | -815M | -923M | - |
| Capital Expenditure | 457M | 5.39M | 2.63M | 279K | 62.2M | 0.00 |
| Free Cash Flow | -2.53B | -800M | -1.23B | -815M | -985M | - |
| Ratios | ||||||
| ROE | -129.9% | -130.8% | -364.2% | -111.8% | -42.5% | -49.2% |
| ROA | -95.8% | -74.0% | -148.5% | -70.6% | -38.6% | -44.2% |
| Net Profit Margin | -222.9% | -98.6% | -211.1% | -108.7% | -112.6% | -169.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ONCOTHERAPY SCIENCE INC. dividends
ONCOTHERAPY SCIENCE INC. has not paid dividends in the last 5 fiscal years.
Last stock split: 3:1 on Sep 27, 2004.
Who owns ONCOTHERAPY SCIENCE INC.
- Insiders 11.46%
- Institutions 2.05%
- Public & others 86.49%
- Shares outstanding 408M
- Free float 381M
ONCOTHERAPY SCIENCE INC. company profile
- Company name
- ONCOTHERAPY SCIENCE INC.
- Ticker
- 30O.F
- ISIN
- JP3202150003
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 46
- Fiscal year end
- March
- Address
- 1-2 Higashida-cho, Kawasaki, Japan, 210-0005
- Phone
- 81 4 4201 6429
- Website
- oncotherapy.co.jp
About ONCOTHERAPY SCIENCE INC.
OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. The company's development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a small molecule TOPK inhibitor currently under non-clinical stage. Its pipeline also comprises cancer peptide vaccines, including S-588410, which completed Phase III clinical trials for the treatment esophageal cancer, as well as Phase II clinical trials for the treatment of bladder cancer; S-488210, which is in Phase I/II clinical trials for the treatment of head and neck cancer; S-588210, which is in Phase I clinical trials for the treatment of solid tumor; and OTSGC-A24, currently in Phase I clinical trials for the treatment of gastric cancer. In addition, the company is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and an anti-amyloid beta peptide antibody that completed Phase I clinical trials for Alzheimer's disease. OncoTherapy Science, Inc. was incorporated in 2001 and is headquartered in Kawasaki, Japan.
ONCOTHERAPY SCIENCE INC. management
3- Mr. Hatsuo KatoExecutive Chairman · born 1943
- Mr. Junichi ShimadaPresident, CEO & Director · born 1961
- Mr. Jae-Hyun ParkChief Scientific Officer, GM of Management Headquarters & Director · born 1976